Cited by 251Medication Adherence and ComplianceBreast Cancer Treatment StudiesCancer survivorship and care

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Adherence to Endocrine Therapy for Breast Cancer

Chlebowski, Rowan T., Geller, Michelle L.·2006·Oncology

Open this paper in CoChat — free account

Abstract

Purpose: Despite the demonstrated efficacy of long-duration adjuvant tamoxifen and aromatase inhibitor use in breast cancer management, information on adherence to such therapy is limited. Therefore, we reviewed the published literature regarding hormonal therapy adherence in clinical trial and practice settings. Methods: A systematic search of the PubMed database, augmented by a review of manuscript references and conference proceedings, commonly identified adherence reports in clinical trials but identified only 9 adherence reports in clinical practice settings. Results: In adjuvant breast cancer clinical trials with longer (≧4 years) follow-up, hormonal therapy (tamoxifen or aromatase inhibitors) was prematurely discontinued by about 23–28% of the study participants. Adherence to aromatase inhibitors did not differ from adherence to tamoxifen in this setting. In breast cancer prevention trials, tamoxifen was prematurely discontinued by 20–46% of the participants. In clinical practice settings, only 2 reports addressed longer-duration (>4 years) adherence to adjuvant tamoxifen use. In these, tamoxifen was prematurely discontinued by 30–50% of the patients. Conclusion: Adherence to prescribed breast cancer hormone therapy has not received concerted attention. Current, albeit limited, evidence suggests long-term hormone therapy adherence may represent an area limiting optimal breast cancer patient treatment.

Integrity signals

Registry

Crossref · 10.1159/000100444

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Adherence to medication.
Osterberg, L., & Blaschke, T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050100 · Cited by 7,974
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
(2005) · The Lancet · doi:10.1016/s0140-6736(05)66544-0 · Cited by 7,626
Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M. T., Cronin, W. M., Vogel, V. G., Robidoux, A., Dimitrov, N. S., Atkins, J. N., et al. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.18.1371 · Cited by 5,450
Cancer Statistics, 2005
Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R. C., Ghafoor, A., Feuer, E. J., & Thun, M. J. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.1.10 · Cited by 4,186
Depression Is a Risk Factor for Noncompliance With Medical Treatment: Meta-analysis of the Effects of Anxiety and Depression on Patient Adherence
DiMatteo, M. R., Lepper, H. S., & Croghan, T. W. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.14.2101 · Cited by 4,177
Effect of Screening and Adjuvant Therapy on Mortality from Breast Cancer
Berry, D. A., Cronin, K. A., Plevritis, S. K., Fryback, D. G., Clarke, L. D., Zelen, M., Mandelblatt, J. S., Yakovlev, A. Y., Habbema, J. D. F., & Feuer, E. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050518 · Cited by 2,456
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer
Howell, A., Cuzick, J. M., Baum, M., Buzdar, A. U., Dowsett, M., Forbes, J., Hoctin-Boes, G., Houghton, J., Locker, G. Y., & Tobias, J. S. (2005) · The Lancet · doi:10.1016/s0140-6736(04)17666-6 · Cited by 2,284
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial
Baum, M., Budzar, A. U., Cuzick, J. M., Forbes, J., Houghton, J., Klijn, J. G. M., & Sahmoud, T. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09088-8 · Cited by 1,958
A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer
Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M., Tu, D., Shepherd, L. E., Pritchard, K. I., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032312 · Cited by 1,795
A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer
Coombes, R. C., Hall, E., Gibson, L. J., Paridaens, R., Jassem, J., Delozier, T., Jones, S. E., Alvarez, I., Bertelli, G., Ortmann, O., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040331 · Cited by 1,759
A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast Cancer
The Breast International Group (BIG) 1-98 Collaborative Group (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052258 · Cited by 1,584
A Randomized Clinical Trial Evaluating Tamoxifen in the Treatment of Patients with Node-Negative Breast Cancer Who Have Estrogen-Receptor–Positive Tumors
Fisher, B., Costantino, J., Redmond, C. K., POISSON, R., Bowman, D., Couture, J., Dimitrov, N. V., Wolmark, N., Wickerham, D. L., Fisher, E. R., et al. (1989) · New England Journal of Medicine · doi:10.1056/nejm198902233200802 · Cited by 1,466
Depression and anxiety in women with early breast cancer: five year observational cohort study
Burgess, C. C., Cornelius, V. R., Love, S., Graham, J., Richards, M. A., & Ramirez, A. J. (2005) · BMJ · doi:10.1136/bmj.38343.670868.d3 · Cited by 1,336
Long-term persistence in use of statin therapy in elderly patients
Benner, J. S. (2002) · JAMA · doi:10.1001/jama.288.4.455 · Cited by 1,232
Screening for Breast Cancer
Elmore, J. G. (2005) · JAMA · doi:10.1001/jama.293.10.1245 · Cited by 1,076
American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Status Report 2004
Winer, E. P., Hudis, C. A., Burstein, H. J., Wolff, A. C., Pritchard, K. I., Ingle, J. N., Chlebowski, R. T., Gelber, R. D., Edge, S. B., Gralow, J. R., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.121 · Cited by 1,026
Self-citation
Patient Race/Ethnicity and Quality of Patient–Physician Communication During Medical Visits
Johnson, R. L., Roter, D., Powe, N. R., & Cooper, L. A. (2004) · American Journal of Public Health · doi:10.2105/ajph.94.12.2084 · Cited by 955
Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial
Powles, T. J., Eeles, R. A., Ashley, S. E., Easton, D. F., Chang, J. C., Dowsett, M., Tidy, A., Viggers, J., & Davey, J. B. (1998) · The Lancet · doi:10.1016/s0140-6736(98)85012-5 · Cited by 897
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early‐stage breast cancer
The ATAC (Arimidex, T. A. O. I. C. T. G. (2003) · Cancer · doi:10.1002/cncr.11745 · Cited by 861
Five Versus More Than Five Years of Tamoxifen Therapy for Breast Cancer Patients With Negative Lymph Nodes and Estrogen Receptor-Positive Tumors
Fisher, B., Dignam, J. J., Bryant, J., DeCillis, A. P., Wickerham, D. L., Wolmark, N., Costantino, J. P., Redmond, C. K., Fisher, E. R., Bowman, D. M., et al. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.21.1529 · Cited by 857
First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial
Cuzick, J. M., Lennard, T., & Working Party and Principal Investigators IBIS (2002) · The Lancet · doi:10.1016/s0140-6736(02)09962-2 · Cited by 745
Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer
Partridge, A. H., Wang, P. S., Winer, E. P., & Avorn, J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.07.071 · Cited by 676
Persistence of Use of Lipid-Lowering Medications
Avorn, J., Monette, J., Lacour, A. S., Bohn, R. L., Monane, M., Mogun, H., & LeLorier, J. (1998) · JAMA · doi:10.1001/jama.279.18.1458 · Cited by 635
Adherence to Therapy With Oral Antineoplastic Agents
Partridge, A. H. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.9.652 · Cited by 585
The Role of Patient-Physician Trust in Moderating Medication Nonadherence Due to Cost Pressures
Piette, J. D., Heisler, M., Krein, S., & Kerr, E. A. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.15.1749 · Cited by 388
Adherence to tamoxifen over the five-year course
Lash, T. L., Fox, M. P., Westrup, J., Fink, A. K., & Silliman, R. A. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9193-0 · Cited by 321
Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring.
Waterhouse, D. M., Calzone, K. A., Mele, C., & Brenner, D. E. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.6.1189 · Cited by 313
Adjuvant Tamoxifen: Predictors of Use, Side Effects, and Discontinuation in Older Women
Demissie, S., Silliman, R. A., & Lash, T. L. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.322 · Cited by 301
Intentional and non-intentional non-adherence to medication amongst breast cancer patients
Atkins, L., & Fallowfield, L. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.03.004 · Cited by 300
Do Patients Treated With Dignity Report Higher Satisfaction, Adherence, and Receipt of Preventive Care?
Beach, M., Sugarman, J., Johnson, R. L., Arbelaez, J., Duggan, P., & Cooper, L. (2005) · Annals of Family Medicine · doi:10.1370/afm.328 · Cited by 286
Patient Beliefs and Tamoxifen Discontinuance in Older Women With Estrogen Receptor—Positive Breast Cancer
Fink, A. K., Gurwitz, J. H., Rakowski, W., Guadagnoli, E., & Silliman, R. A. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.064 · Cited by 282
Compliance with antihypertensive therapy among elderly Medicaid enrollees: the roles of age, gender, and race.
Monane, M., Bohn, R. L., Gurwitz, J. H., Glynn, R., Levin, R., & Avorn, J. (1996) · American Journal of Public Health · doi:10.2105/ajph.86.12.1805 · Cited by 253
Adherence beliefs among breast cancer patients taking tamoxifen
Grunfeld, E. A., Hunter, M. S., Sikka, P., & Mittal, S. (2004) · Patient Education and Counseling · doi:10.1016/j.pec.2004.10.005 · Cited by 245
Strategies for Optimizing Adherence to Highly Active Antiretroviral Therapy: Lessons from Research and Clinical Practice
Stone, V. E. (2001) · Clinical Infectious Diseases · doi:10.1086/322698 · Cited by 220
American Society of Clinical Oncology Technology Assessment of Pharmacologic Interventions for Breast Cancer Risk Reduction Including Tamoxifen, Raloxifene, and Aromatase Inhibition
Chlebowski, R. T., Col, N. F., Winer, E. P., Collyar, D. E., Cummings, S. R., Vogel, V. G., Burstein, H. J., Eisen, A. F., Lipkus, I. M., & Pfister, D. G. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.06.029 · Cited by 197
Self-citation
A Teachable Moment for Oncologists: Cancer Survivors, 10 Million Strong and Growing!
Ganz, P. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.916 · Cited by 165
PATIENT-PROVIDER COMMUNICATION: THE EFFECT OF RACE AND ETHNICITY ON PROCESS AND OUTCOMES OF HEALTHCARE
Racial, E., Smedley, B. D., Stith, A. Y., & Nelson, A. R. (2003) · Cited by 162
Helping Patients Follow Prescribed Treatment: Clinical Applications
Haynes, R. B., McDonald, H. P., & Garg, A. X. (2002) · JAMA · doi:10.1001/jama.288.22.2880 · Cited by 98 · cited 1×
“While evidence indicates that chronic disease patients take only about half of their prescribed medications, adherence has been considered to be less of an issue for cancer patients, who are regarded as highly motivated due to the seriousness of their disease and the risk associated with nonadherence [”
Background
Persistence with drug therapy: a practical approach using administrative claims data.
Dezii, C. M. (2001) · PubMed · Cited by 93
Readability and content analysis of print cholesterol education materials
Glanz, K., & Rudd, J. (1990) · Patient Education and Counseling · doi:10.1016/0738-3991(90)90085-y · Cited by 70
Prevention of Hormone-Related Cancers: Breast Cancer
Dunn, B. K., Wickerham, D. L., & Ford, L. G. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.028 · Cited by 69
Non-adherence to endocrine therapy for breast cancer
Partridge, A. H. (2006) · Annals of Oncology · doi:10.1093/annonc/mdj141 · Cited by 55
Association of Tamoxifen (TAM) and TAM Metabolite Concentrations with Self-Reported Side Effects of TAM in Women with Breast Cancer
Gallicchio, L. M., Lord, G. A., Tkaczuk, K., Danton, M., Lewis, L. M., Lim, C. K., & Flaws, J. A. (2004) · Breast Cancer Research and Treatment · doi:10.1023/b:brea.0000021050.92539.b0 · Cited by 50
Physician recommendations regarding tamoxifen and patient utilization of tamoxifen after surgery for ductal carcinoma in situ
Yen, T. W. F., Hunt, K. K., Mirza, N. Q., Thomas, E. S., Singletary, S. E., Babiera, G. V., Meric‐Bernstam, F., Buchholz, T. A., Feig, B. W., Ross, M. I., et al. (2004) · Cancer · doi:10.1002/cncr.20085 · Cited by 47
Adherence and persistence: Impact on outcomes and health care resources
Reginster, J. (2006) · Bone · doi:10.1016/j.bone.2005.11.013 · Cited by 44
Tamoxifen non-compliance: does it matter?
Murthy, V., Bharia, G., & Sarin, R. (2002) · The Lancet Oncology · doi:10.1016/s1470-2045(02)00895-1 · Cited by 33
Safety Considerations of Adjuvant Therapy in Early Breast Cancer in Postmenopausal Women
Gradishar, W. J. (2005) · Oncology · doi:10.1159/000087282 · Cited by 31
Breast carcinoma chemoprevention in the community setting
Brewster, A. M., Christo, D. K., Lai, H. C., & Helzlsouer, K. J. (2005) · Cancer · doi:10.1002/cncr.20882 · Cited by 13
[Drug compliance in type 2 diabetes: role of drug treatment regimens and consequences on their benefits].
Penfornis, A. (2003) · PubMed · Cited by 10
Compliance and persistence of tamoxifen and aromatase inhibitors in breast cancer patients
Martin, B. P., Barghout, V. E., & Hutchins, L. F. (2006) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(06)80201-6 · Cited by 5

Flagged first, then by citations

Research works printed but not linked: 1

10.1016%2FS0140-6736%2805%2974803-0 · DOI

Sorted by citations

Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer
Hershman, D. L., Shao, T., Kushi, L. H., Buono, D., Tsai, W. Y., Fehrenbacher, L., Kwan, M., Gomez, S. L., & Neugut, A. I. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1132-4 · Cited by 870
Early Discontinuation and Nonadherence to Adjuvant Hormonal Therapy in a Cohort of 8,769 Early-Stage Breast Cancer Patients
Hershman, D. L., Kushi, L. H., Shao, T. H., Buono, D. L., Kershenbaum, A., Tsai, W., Fehrenbacher, L., Gomez, S. L., Miles, S. Q., & Neugut, A. I. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.9655 · Cited by 834
American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer
Burstein, H. J., Prestrud, A. A., Seidenfeld, J., Anderson, H., Buchholz, T. A., Davidson, N. E., Gelmon, K. A., Giordano, S. H., Hudis, C. A., Malin, J. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3756 · Cited by 799
Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review
Murphy, C. C., Bartholomew, L. K., Carpentier, M. Y., Bluethmann, S. M., & Vernon, S. W. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2114-5 · Cited by 708
Patient adherence and persistence with oral anticancer treatment
Ruddy, K., Mayer, E., & Partridge, A. (2009) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20004 · Cited by 569

See all 251

Authors: Chlebowski, R. T., & Geller, M. L.
Affiliations: The Lundquist Institute (US)
ORCID: Chlebowski, Rowan T.
Venue: Oncology
Publisher: S. Karger AG
Published: 2006
Volume: 71
Issue: 1-2
Pages: 1-9
ISSN: 0030-2414 (ISSN-L)
1423-0232
DOI: 10.1159/000100444
OpenAlex: W1540562253
Cited by: 251
References: 50
Citations by year: 2026: 5 · 2025: 6 · 2024: 9 · 2023: 6 · 2022: 8 · 2021: 7 · 2020: 4 · 2019: 7 · 2018: 6 · 2017: 9 · 2016: 12 · 2015: 9 · 2014: 21 · 2013: 14 · 2012: 22
FWCI: 3.00
Type: journal article
Language: en
Open access: closed
Licence: www.karger.com/Services/SiteLicenses (vor)
www.karger.com/Services/SiteLicenses (tdm)
Locations: Oncology (publishedVersion)
PubMed (publishedVersion)
Funders: AstraZeneca
Topics: Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Health Sciences › Medicine › Oncology › Cancer survivorship and care
Keywords: medication adherence, breast cancer, adjuvant endocrine therapy, tamoxifen, aromatase inhibitors, premature discontinuation, Breast Cancer Prevention Trial
MeSH terms: Administration, Oral, Breast Neoplasms, Clinical Trials as Topic, Female, Humans, Patient Compliance, Tamoxifen, Antineoplastic Agents, Hormonal, Aromatase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Adherence to Endocrine Therapy for Breast Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks